Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation

Abstract

Background-Despite the use of heparin, aspirin, and other antiplatelet agents, acute coronary syndrome patients without ST-segment elevation remain at risk of cardiovascular thrombotic events. Given the role of inflammation in the pathogenesis of arterial thrombosis, we tested the hypothesis that the combination of meloxicam, a preferential COX-2 inhibitor, and heparin and aspirin would be superior to heparin and aspirin alone. Methods and Results-In an open-label, randomized, prospective, single-blind pilot study, patients with acute coronary syndromes without ST-segment elevation were randomized to aspirin and heparin treatment (nϭ60) or aspirin, heparin, and meloxicam (nϭ60)

Evaluation of the Effect of Andrographolide on Atherosclerotic Rabbits Induced byPorphyromonas gingivalis

“…IL-1 β immune reactivity is found in monocyte, macrophage, EC, and VSMC in human and experimental atherosclerotic plaque. According to several epidemiological and experimental studies, natural or synthetic products, having anti-inflammatory action, are proven to have a strong preventive effect on the development of atherosclerosis [42]. To investigate the potential anti-inflammatory activity of AND as an antiatherogenic agent, we had evaluated the role of AND on the inflammatory progression of early atherosclerosis in rabbits.…”

Rofecoxib, a COX-2 Inhibitor, Lowers C-Reactive Protein and Interleukin-6 Levels in Patients With Acute Coronary Syndromes

“…The author concludes that, "the current available COX-2 inhibitors might provide a novel form of therapy for plaque stabilization of patients with atherosclerotic disease and prevention of acute ischemic syndromes." 40 In a study by Altman et al, 41 the use of aspirin plus meloxican, a COX-2 inhibitor, for 30 days in patients with ACS without ST-segment elevation was associated with lower rate of recurrent angina, myocardial infarction (MI), or death. An interesting experiment by Saito et al 42 showed better cardiac function in rats that received a selective COX-2 inhibitor after ligation of the left coronary artery in contrast to the control group.…”

Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders

“…However, the evidence consistently shows worse clinical outcome with their use [49]. To refine this therapy, the NUT-2 trial (Non-steroidal anti-inflammatory drugs in Unstable angina Treatment) utilised meloxicam, a cyclo-oxygenase 2 (COX-2) selective inhibitor, which produced significant reductions in mortality and further MI rates after 90 days [50]. Despite this promising early result, a 2006 meta-analysis concluded that selective COX-2 inhibitors are associated with an increased risk of vascular events [51].…”